Sacre JW, Magliano DJ, Shaw JE. Clinical Utility of Cardiovascular Risk Scores for Identification of People With Type 2 Diabetes More Likely to Benefit From Either GLP-1 Receptor Agonist or SGLT2 Inhibitor Therapy. Diabetes Care 2022 Jul 1. pii: 147158. doi: 10.2337/dc21-1929.
PMID: 35775451